

Broadview Ventures | 265 Franklin Street, Suite 1902 | Boston MA, 02110 | broadviewventures.org | 617.459.4686

2025 PORTFOLIO MOMENTUM

- Broadview portfolio companies raised \$285M of funding in 2025
- We are thrilled to have co-invested with top-tier syndicate partners in 2025, including Alexandria Venture Investments, ATHOS, Atlas Venture, BDC Capital, Desjardins Capital, Earlybird Venture Capital, Epidarex Capital, F-Prime Capital, GV, KF Matheson, Lilly Asia Ventures, Lilly, Lumira Ventures, +ND Capital, NEA, Sofinovva Partners, and Vensana Capital
- The pipeline remained robust with more than 700 investment opportunities considered
- Most importantly, Broadview's portfolio companies have touched the lives of more than 800,000 patients to date

PORTFOLIO MILESTONE HIGHLIGHTS

- **Vectorious** was acquired by Edwards to advance its V-LAP implantable pressure sensor
- **AtaCor** signed a collaboration agreement with Abbott to initiate the pivotal ALARION EV Study evaluating the parasternal EV-ICD system
- **18** companies conducted clinical studies, including **6** pivotal trials
- **Basking Biosciences** received approval by U.S., Canadian, and Australian regulatory bodies to move ahead with Phase 2 proof-of-concept clinical study in stroke patients
- **Cardiosense** received FDA 510(k) clearance for CardioTag for non-invasive ECG, PPG, and SCG measurement

LONGVIEW VENTURES


Longview Ventures continued a steady pace of investment activity in 2025, focusing on select Broadview clinical-stage opportunities as a complement to Broadview's dedication to Seed and Series A financings.

2025 INVESTMENTS


- **HAYA Therapeutics**—\$65M Series A to fund Phase 1a/b study in non-obstructive hypertrophic cardiomyopathy
- **Puzzle Medical**—\$30M Series A-2 to fund feasibility studies and pivotal readiness in patients with ADHF
- **Comanche Bio**—Series B extension closed to fund completion of global Phase 2a study in pregnant preeclampsia patients

Our mission is to accelerate the development of promising technology for the diagnosis and treatment of cardiovascular disease and stroke through targeted investments.

BROADVIEW AND LONGVIEW'S INVESTMENTS ARE LEVERAGED 18.1X BY CO-AND FOLLOW-ON INVESTMENTS AND NON-DILUTIVE GRANT FUNDING



BROADVIEW INVESTMENTS BY INDICATION



TALENT

Chris Colecchi, the Founding Managing Director of Broadview, has transitioned to an advisory capacity after 18 years of leading the Broadview and Longview investment team and activities. In a part-time capacity, Chris will continue to support Broadview's efforts, focusing on professional development of the team and further advancement of the Broadview strategy and mission.

Thomas Needham, who joined Broadview in 2018, was promoted to Managing Director of Broadview. Tom leads the Biopharmaceuticals practice and oversees Broadview investment strategy and venture portfolio management activities. He also serves as Managing Director of Longview Ventures. Tom has 30 years of experience in venture capital investing, business development, corporate strategy, and C-suite executive management responsibilities in public and private life science companies.

Daniel Gottlieb, who joined Broadview in 2019, was promoted to Managing Director of Broadview. Daniel leads the MedTech practice and oversees Broadview investment operations and organizational development. Daniel has spent his career focused on the development and commercialization of treatments for cardiovascular disease, including experience in large multinationals and startup environments across medical devices and biotech.

Ian Meredith, MBBS, PhD, joined Broadview's Strategic Advisory Board. Dr. Meredith is currently a Vice Chancellor's Professorial Fellow at Monash University in Melbourne, Australia and a non-executive director serving on the boards of both US and Australian private and public companies. He recently retired as the Executive Vice President and Global Chief Medical Officer at Boston Scientific in 2023.



BROADVIEW TEAM

MANAGEMENT

Daniel Gottlieb
Managing Director
Tom Needham
Managing Director
Christopher Colecchi
Founding Managing Director

INVESTMENT TEAM

Christopher de Souza, PhD
Benjamin Kreitman
Hewmun Lau
David Milan, MD
Khushbu Modi
Nichole Neal, MBA
David Prim, PhD
Sunny Varshney, MD

STRATEGIC ADVISORY BOARD

Eugene Braunwald, MD
Costantino Iadecola, PhD
Joseph Loscalzo, MD, PhD
Michael Mendelsohn, MD
Ian Meredith, MBBS, PhD
Eric Rose, MD
Hugh Watkins, MD, PhD

ADVISORS

Annabel Chen-Tournoux, MD
Teo Dagi, MD
Marc Semigran, MD
Vivian Taqueti, MD, MPH



LONGVIEW TEAM

MANAGEMENT

Tom Needham
Managing Director
Christopher de Souza, PhD
Daniel Gottlieb
Benjamin Kreitman
Hewmun Lau
Khushbu Modi
Nichole Neal, MBA
David Prim, PhD
Sunny Varshney, MD

INVESTMENT ADVISORY COMMITTEE

External Members
Jan Garfinkle
Terry McGuire
Chris Mirabelli, PhD
Eric Rose, MD

Leducq Members
Martin Landaluce
David Milan, MD
David Tancredi, MD, PhD

INVESTMENTS THROUGH 2025

Company	Technology/Therapy	Founders/Management
2024		
IsomAb Bio	anti-VEGFA ₁₆₅ b antibody for the treatment of stable angina	Dave Bates, Philip Brainin, Anker Lundemose
CorFlow	combination diagnostic and drug delivery platform for MVO	Paul Mead, Rob Schwartz, Martin Rothman
Alveron Pharma	reversal agent for intracerebral hemorrhage	Ben Nichols, Stephan Peters
Mosanna Therapeutics	intranasal spray for obstructive sleep apnea	David Weber, Jonathan Talbot, Sascha Oliver Bucher
Relief Cardiovascular	renal vein unloading system for diuretic resistant HF	Alexander Cooper, Brent Ratz, Arshad Quadri
2022		
Puzzle Medical	percutaneous heart pump for patients with advanced HF	Jade Doucet-Martineau, Gabriel Georges, Francois Trudeau
Nyra Medical	transcatheter implant to treat mitral valve regurgitation	Lori Chmura, Murali Padala, Eric Sarin
Cardiosense	noninvasive sensor and algorithms for heart failure management	Eric Meizlish, Omer Inan, Andrew Carek
2021		
XII Medical	minimally-invasive technology to address obstructive sleep apnea	Garrett Schwab, Anthony Caparso
RapidPulse	aspiration system to treat acute ischemic stroke	Sean McBrayer, David Gill, Carlos Rivera
Comanche BioPharma	siRNA therapeutic for the treatment of preeclampsia	T. Scott Johnson, Mike Young, Craig Mello
2020		
Antag Therapeutics	GIPR antagonist for obesity	Joerg Moeller, Alexander Sparre-Ulrich, Jens Juul Holst
Basking Biosciences	reversible anti-vWF aptamer for acute ischemic stroke	Julia Owens, Shahid Nimjee, Bruce Sullenger
HAYA Therapeutics	ncRNA-targeting antifibrotic therapeutics for heart failure	Samir Ounzain, Daniel Blessing
2019		
Alleviant Medical	atrial shunt for the treatment of heart failure	Jacob Kriegel, Adam Berman, Mary Byron
Renovacor*	BAG3 gene therapy for a rare, familial form of dilated cardiomyopathy	Maggie Cook, Arthur Feldman
CroïValve	percutaneously implanted device for tricuspid regurgitation	Lucy O'Keffe, Martin Quinn
2018		
AtaCor Medical	leadless extravascular pacing and defibrillation systems	Rick Sanghera, Sean McGeehan, Alan Marcovecchio
Kantum Pharma	P2Y14 inhibitor for cardiac surgery-associated acute kidney injury	Sylvie Breton, Glenn Batchelder
2017		
NIDO Surgical*	device for epicardial ablation of ventricular tachycardia	Pedro del Nido, Nikolay Vasilyev, Thomas Marchand
Mellitus	novel biomarker for the screening and diagnosis of gestational diabetes	Jose Halperin, Michael Choren
Adient	bioresorbable IVC filter for prevention of pulmonary embolism	Mitch Eggers, Joseph Steele
Vectorious*	direct left atrial pressure sensor	Oren Goldstein, Eyal Orion
EP Sciences	novel defibrillation waveform to reduce pain associated with ICD therapies	Ron Berger, Howard Levin
2016		
FineHeart	fully implantable, miniaturized circulatory support device for HF	Arnaud Mascarell, Stephane Garrigue, Jean-Luc Boulnois
Gila Therapeutics	topical lingual PYY agonist for treatment of obesity	Tom Vasicek, Rich Horan
Aeromics	small molecule for stroke-related cerebral edema	Tom Zindrick, Trevor Thompson
2015		
Pulmokine*	small molecule for pulmonary artery hypertension	Larry Zisman, Shreefal Mehta
Lyra Therapeutics*	bioresorbable platform for multiple indications	Bob Langer, George Whitesides, Maria Palasis
Eprium Bio (Cardero)	mitochondrial biogenesis platform technology	Alexander Casdin, George Schreiner, Sundeep Dugar

* Exited

INVESTMENTS THROUGH 2025

Company	Technology/Therapy	Founders/Management
2014		
ZZ Biotech	<i>mutant APC peptide therapeutic for stroke</i>	Berislav Zlokovic, Kent Pryor, Joseph Romano
Ischemia Care	<i>immune cell gene expression profile diagnostic for stroke</i>	Jeff June
Acesion Pharma	<i>Small molecule to treat chronic atrial fibrillation</i>	Ulrik Sørensen, Morten Grunnet, Anders Gaarsdal Holst
Aria CV	<i>counterpulsation device for pulmonary hypertension</i>	John Scandurra, Karl Vollmers, Dan Gladney
2013		
Zumbro Discovery	<i>peptide therapeutic for treatment of resistant hypertension</i>	John Burnett, Horng Chen
BioKier	<i>small molecule anti-diabetic treatment</i>	George Szewczyk, Roger Nolan
Remedy*	<i>small molecule for the treatment of central nervous system edema</i>	Sven Jacobson
GI Windows	<i>non-surgical approach to gastric bypass</i>	Chris Thompson, Marvin Ryou
2012		
VGS	<i>external support for saphenous vein grafts in CABG</i>	Eyal Orion
InfoBionic	<i>cloud-based remote monitoring platform for atrial fibrillation</i>	Jeremy Ruskin, Stuart Long
Herantis*	<i>VEGF based gene therapy for lymphedema</i>	Antti Vuolanto
Declimmune	<i>MAb for treatment of post MI and I/R injury</i>	Christopher Mirabelli, Walter Newman
2011		
Cardialen	<i>implantable cardioversion for the treatment of atrial fibrillation</i>	Igor Efimov, Jeff Peters
NuPulse	<i>counterpulsation device for the treatment of heart failure</i>	Valluvan Jeevanandam, Douglas Altschuler
Aggamin	<i>sFlt-1 apheresis treatment for preeclampsia</i>	Ravi Thadhani, Paul Kussie, Ananth Karumanchi
Provasculon*	<i>peptide therapeutics for treatment of myocardial infarction</i>	Rich Lee, Roger Kitterman
Apama*	<i>novel ablation system for treatment of atrial fibrillation</i>	Amr Salahieh
2010		
Allosteros	<i>CaMKII inhibitors for heart failure and atrial fibrillation</i>	Howard Schulman, Mark Anderson
Intravascular Imaging	<i>NIRF device for intracoronary artery imaging</i>	Farouc Jaffer, Vasilis Ntziachristos
Capricor*	<i>allogeneic stem cell therapy after myocardial infarction</i>	Eduardo and Linda Marbán
CellAegis	<i>remote ischemic conditioning for myocardial infarction</i>	Andrew Redington, Chris Calderone
2009		
CardiAQ Valve*	<i>transcatheter mitral valve</i>	Brent Ratz, Arshad Quadri, Rob Michiels
VentriNova	<i>gene therapy for regeneration of cardiac tissue</i>	Hina Chaudhry
miRagen*	<i>microRNAs for cardiovascular and oncology indications</i>	Bruce Booth, Mike Bristow, Eric Olson

* Exited